Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., a publicly traded entity (NASDAQ: IONS), stands as a leader in RNA-targeted therapeutics. Founded in 1989, the company has pioneered antisense technology, RNA interference, and CRISPR therapeutics from its base in Carlsbad, California. Ionis Pharmaceuticals focuses on discovering and developing innovative medicines for severe diseases, including cardiovascular, metabolic, neurological disorders, rare genetic conditions, and cancer. Their proprietary antisense technology platform is designed to create first-in-class and best-in-class treatments by targeting RNA to precisely modulate protein production. This advanced approach allows for the development of novel therapies aimed at unmet medical needs across a broad spectrum of indications. The company operates with a significant employee base, ranging from 1,000 to 5,000 individuals, dedicated to advancing its pipeline.

The company's operational footprint includes its headquarters in Carlsbad, California, from which it manages its extensive research and development efforts. Ionis Pharmaceuticals is committed to translating its scientific expertise into tangible patient benefits, with a robust pipeline of drug candidates. Learn about Ionis Pharmaceuticals' global headquarters for detailed location information. The organization's strength lies in its dedicated team of scientists and professionals, working collaboratively to push the boundaries of genetic medicine. Meet Ionis Pharmaceuticals' team to understand the expertise driving their innovation and development processes.

With a reported revenue of $1.1B, Ionis Pharmaceuticals is a significant player in the biotechnology sector, competing with established pharmaceutical giants and emerging biotechs. Its strategic focus on RNA-based therapies positions it within a dynamic and rapidly evolving market. The company's commitment to innovation is underscored by itsView more...